Introduction
Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that bind to the PPAR response element (PPRE) on DNA as a heterodimer with retinoid X receptor-α (RXR-α), and mediate ligand-dependent transactivation (1) . There are 3 known isoforms of PPARs, PPAR-α, Recently, several studies have suggested the functional significance of PPARs in renal pathophysiology (4) . It is assumed that PPAR-α is involved in the control of fatty acid β-oxidation and the regulation of cytochrome P450 4A genes in the kidney (4, 5) , and this isoform may affect sodium retention (4) . Moreover, Kamijo et al. recently demonstrated that PPAR-α in the proximal tubules was involved in the maintenance of ATP homeostasis to degrade absorbed proteins (6) . PPAR-γ ligand TZDs are reported to ameliorate albuminuria in either streptozotocine-induced (7, 8) or Zucker fatty diabetic rats (9) , and to reduce proteinuria and glomerulosclerosis in 5/6 nephrectomized rats (10) independent of blood pressure-lowering effects or insulin-sensitization. However, it has not yet been clarified how and where the actions of PPARs take place.
Several studies have examined the localization of PPAR expression in the kidney (11) (12) (13) . Using an in situ hybridization (ISH) method, Braissant et al. reported that PPAR-α mRNA was expressed at the proximal tubules and glomeruli, while PPAR-γ mRNA expression was limited to the proximal tubules in the rat kidney (11) . Guan et al. also performed ISH using rabbit and human kidneys, and showed that PPAR-α mRNA was expressed at the proximal tubules and medullary thick ascending limbs of Henle, while PPAR-γ mRNA was expressed at medullary collecting ducts (12) . In addition, Yang et al. demonstrated PPAR-α mRNA expression at the proximal tubules and PPAR-γ mRNA expression at the proximal tubules, medullary thick ascending limbs of Henle, and medullary collecting ducts by reverse transcription (RT)-polymerase chain reaction (PCR) in the rat kidney (13) . All these reports are thus inconsistent each other, and demonstrate limited expression of PPARs in the restricted nephron segments. Thus, while the results of these reports are generally incompatible, they all demonstrate a limited expression of PPARs in the restricted nephron segments. Therefore, there exists a discrepancy between the reported localization of PPAR expression, and the reported function of PPARs that are widely observed along the nephron segments. Moreover, these reports have been limited to the mRNA level, and there have been few reports on the protein expression of PPARs in the kidney. In the present study, we generated isoform-specific anti-PPAR antibodies, and examined the precise localization of the protein expression of PPARs in the kidney.
Methods

Preparation of Synthetic Peptides and Immunization
Synthetic peptides containing the following mouse PPAR amino acid residues were used in the immunizations: PPAR-α (1-18) (2), PPAR-γ 1 (60-79) (3), and PPAR-γ 2 (14-30) (3) (Fig. 1) . These particular amino acids were chosen as epitopes because of their location in regions unique to each PPAR isoform and the high antigenicity index of their amino acid sequences, as determined by computer analysis. As indicated in Fig. 1 , the antibody raised against PPAR-γ 1 (60-79) may recognize both PPAR-γ 1 and -γ 2. Moreover, their sequences were identical between the mouse and rat. These peptides were synthesized, conjugated to Keyhole Limpet Hemocyanin via m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester, and used to immunize rabbits as previously described (14) . The titer of each antiserum was screened using an enzyme-linked immunoabsorbant assay containing immunizing peptide as previously described (14) .
Plasmids/in Vitro Translation
The mouse PPAR-α expression plasmid in pCMX (15) was provided by K. Umesono (Kyoto University, Kyoto, Japan). The mouse PPAR-δ (β) expression plasmid in pCMX (15) was provided by R.M. Evans (Salk Institute, La Jolla, USA). Mouse PPAR-γ 1 and -γ 2 expression plasmids in pSG5 (16) were provided by S.A. Kliewer (Glaxo Wellcome, Research Triangle Park, USA). These expression plasmids and the mouse RXR-α expression plasmid in pcDNA1/Amp (17) were in vitro translated using a TNT TM Kit (Promega, Madison, USA) either in the absence or presence of 35 Smethionine according to the manufacturer's instructions.
Preparation of Rat Kidney Nuclear Extracts/Western Immunoblot Analyses
Adult male Sprague-Dawley (SD) rats (200-250 g) were anesthetized with diethyl ether, and perfused with saline through cannulae inserted into the left ventricles. Their kidneys were removed and divided into the cortex and the medulla. Then their nuclear extracts were prepared as previously described (18) . Twenty micrograms of rat kidney nuclear extracts or 15 µl of each in vitro translated PPAR isoform protein were subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) (9% acrylamide gel). After SDS-PAGE, proteins were transferred to polyvinylidene difluoride (PVDF) (Immobilon P, Millipore, Bedford, USA), and immunoblot analyses were performed as previously described (14) using a 1:500 dilution of each anti-PPAR antibody as the primary antibody and 1:2000 diluted horseradish peroxidase-linked donkey antirabbit Ig (Amersham Biosciences, Buckinghamshire, UK) as the secondary antibody. In some experiments, each anti-PPAR antibody was incubated with the same volume of phosphate buffered saline (PBS) or the respective immunizing peptide in PBS (1 mg/ml) for 1 h at 4 ºC prior to immunoblotting (14) . All procedures conformed to the NIH Guide for the Care and Use of Laboratory Animals, and were approved by the Tohoku University School of Medicine Animal Use and Care Committee.
Immunoprecipitations
Each in vitro translated 35 S-labeled PPAR isoform protein (10 µl) was incubated with the respective anti-PPAR antibody for 2 h at 4ºC, and was subsequently precipitated with 10% (v/v) Pansorbin (Calbiochem, San Diego, USA) as previously described (14) . Precipitant was collected and electrophoresed with the same amount of input protein. In some experiments, each anti-PPAR antibody was incubated with the same volume of PBS or the respective immunizing peptide in PBS (1 mg/ml) for 1 h at 4 ºC prior to immunoprecipitation (14) .
Electrophoretic Mobility Shift Assay (EMSA)
EMSA using 32 P-labeled HMG-CoA synthase gene PPRE (HMGS-PPRE) as a probe was performed as previously described (19) . Briefly, the probe was incubated either with 2 µl in vitro translated RXR-α and/or PPAR isoform, or 2 µg rat kidney nuclear extracts for 30 min at room temperature, and was subjected to electrophoresis on 4% polyacrylamide gels. For antibody supershift experiments, 1 µl anti-PPAR antibody or non-immune rabbit serum was added to the samples, which were then incubated for an additional 2 h at 4 ºC before being analyzed by electrophoresis (14, 19) . For the competition experiment, the samples were co-incubated with a 100-fold excess of unlabeled oligonucleotides for HMGS-PPRE.
RNA Preparation/Semi-Quantitative RT-PCR
Total RNAs of the cortex or medulla were extracted from kidneys of adult male SD rats using an RNeasy mini kit (Quiagen, Tokyo, Japan) according to the manufacturer's instructions. The extracted RNAs (1 µg) were then subjected to RT-PCR using primers specific for either rat PPAR-γ (forward primer: 5 -GTTCATGCTTGTGAAGGATGC-3 ; reverse primer: 5 -ACTCTGGATTCAGCTGGTCG-3 ) (19) or β-actin (forward primer: 5 -GGGAAATCGTGCGTGAC AT-3 ; reverse primer: 5 -CAGGAGGAGCAATGATCTT-3 ) (20) under the following conditions simultaneously: 30 min at 50 ºC and 2 min at 94 ºC for RT, followed by 28 cycles of 30 s at 94 ºC, 30 s at 60 ºC, and 1.5 min at 72 ºC for PCR. In the PCR condition, a linear correlation between the PCR cycles and the densitometry intensity of PCR products was confirmed.
Immunohistochemistry
Adult male SD rats were anesthetized with diethyl ether, and perfused with saline through cannulae inserted into the left ventricles. Their kidneys were removed and fixed for 24 h with 20% formaldehyde, and mounted onto paraffin blocks. Each 2 µm-thick section was deparaffined and rehydrated with PBS. The samples were then microwaved at 100 ºC for 10 min for the retrieval of antigenicity, and were incubated with 3% hydrogen peroxide in PBS for 10 min to block endogenous peroxidase activity. Each anti-PPAR antibody was used at a dilution of 1:1,500 (PPAR-α) or 1:3,000 (PPAR-γ 1). The samples were incubated with each antibody at 37 ºC for 60 min. Staining was performed with EnVision (Dako, Carpinteria, USA) and a VIP Substrate Kit (Vector Laboratories, Burlingame, USA). The specificity of the immunohistochemical reaction was established by pre-absorption of each anti-PPAR antibody with 10 4 mol/l of the respective immunizing peptide overnight at 4 ºC before the immunohistochemical procedure (14) .
Results
Characterization of Anti-PPAR Antibodies
To characterize the specificity of each antibody, we first performed Western immunoblot analyses (Fig. 2) . Each PPAR isoform protein synthesized in vitro either in the presence or absence of 35 S-methionine was electrophoresed simultaneously. Lanes 1-4 indicate 35 S-labeled PPARs. In contrast to PPAR-γ 1 in lane 3, PPAR-γ 2 in lane 4 consists of two bands representing PPAR-γ 2 (the upper band) and PPAR-γ 1 (the lower band). The PPAR-γ 1 was most likely translated from internal methionine at the 31st amino acid residue from PPAR-γ 2 mRNA (Fig. 1) . Lanes 5-16 indicate immunoblot analyses of unlabeled PPAR isoform proteins using anti-PPAR antibodies. As shown in lanes 5-8, anti-PPAR-α antibody specifically detected PPAR-α protein (lane 5). As shown in lanes 13-16, anti-PPAR-γ 2 antibody specifically detected PPAR-γ 2 protein (lane 16). Anti-PPAR-γ 1 antibody (lanes 9-12) detected both PPAR-γ 1 protein (lanes 11 and 12) and PPAR-γ 2 protein (lane 12) as expected from its epitope location (Fig. 1) .
We next performed immunoprecipitations using 35 S-labeled PPARs (Fig. 3) . Anti-PPAR-α antibody immunoprecipitated most of the input PPAR-α protein (lanes 1 and 2), and the immunoprecipitation was specifically inhibited by pre-incuba-tion with its immunizing peptide (lane 3). Anti-PPAR-γ 1 antibody also immunoprecipitated most of the input PPAR-γ 1 protein (lanes 4 and 5), and the immunoprecipitation was specifically inhibited by pre-incubation with its immunizing peptide (lane 6). In case of anti-PPAR-γ 2 antibody, it specifically immunoprecipitated most of the input PPAR-γ 2 protein and did not affect PPAR-γ 1 protein (lanes 7 and 8), and the immunoprecipitation was specifically inhibited by pre-incubation with its immunizing peptide (lane 9).
The specificity of each antibody was further characterized by antibody supershift experiments in EMSA using in vitro translated PPARs and RXR-α (Fig. 4) . These data indicate that each anti-PPAR antibody can specifically recognize the respective PPAR isoform protein, as demonstrated by Western immunoblot analyses, immunoprecipitations, and antibody supershift experiments in EMSA.
PPAR Protein Expression in the Rat Kidney
Western immunoblot analyses using rat kidney nuclear extracts were first performed using these antibodies (Fig. 5A ). In the rat kidney cortex, expression of both PPAR-α protein (lane 1) and PPAR-γ 1 protein (lane 5) was detected by the respective antibodies. Weak expression of PPAR-γ 1 protein was also observed in the medulla (lane 6). Detection of these proteins was inhibited by pre-incubation of each antibody with the respective immunizing peptide (lanes 3, 7, and 8), suggesting that the detected proteins were specific. Expression of PPAR-γ 2 protein was not observed either in the cortex (lane 9) or in the medulla (lane 10). These data suggest that PPAR-α and PPAR-γ 1 proteins, but not PPAR-γ 2 protein, are expressed in the rat kidney. We next performed antibody supershift experiments in EMSA (Fig. 5B) . Interestingly, protein-DNA complexes formed with nuclear extracts of cortex were composed of two bands (lanes 2 and 11), while those formed with nuclear extracts of medulla were composed of one band (lanes 6 and 13). Although the reason for the difference in formation of protein-DNA complexes between the cortex and medulla remains uncertain, all these complexes were demonstrated to be specific, since their formation was completely inhibited by a competition experiment using excess amounts of unlabeled oligonucleotides for HMGS-PPRE (lanes 10-14) . The protein-DNA complexes formed with nuclear extracts of cortex (lane 2) or medulla (lane 6) were partially supershifted by anti-PPAR-α antibody (lanes 4 and 8) or anti-PPAR-γ 1 antibody (lanes 5 and 9), but not by non-immune rabbit serum (lanes 3 and 7) . These data suggest that PPAR proteins are involved in the protein-DNA complexes. The discrepancy between the immunoblot analyses and antibody supershift experiments in EMSA with respect to PPAR-α expression in the medulla may have been due to the difference of detection threshold level between them. Since previous studies have demonstrated a predominant expression of PPAR-γ mRNA in the medulla (11-13), we next performed semi-quantitative RT-PCR to examine PPAR-γ 1 expression at the mRNA level. In contrast to its protein expression level (Fig. 5A, lanes 5 and  6) , PPAR-γ 1 mRNA was more abundantly expressed in the medulla (Fig. 5C, lane 2) than in the cortex (Fig. 5C, lane 1) , which was consistent with the previous studies (11) (12) (13) .
In order to further localize the expression of each PPAR isoform protein in the nephron segments, immunohistochemical analyses were next performed. Figure 6A demonstrates the results of immunohistochemical studies using anti-PPAR-α antibody. In the cortex of the rat kidney (upper left and upper right), PPAR-α was expressed in the nuclei of glomeruli, proximal tubules (indicated by a large arrowhead), and distal tubules (indicated by a small arrowhead). In the glomeruli, PPAR-α was mainly expressed in mesangial
Fig. 4. Antibody supershift experiments in EMSA of in vitro translated PPAR isoform proteins using anti-PPAR antibodies. EMSA was performed using in vitro translated PPARs and RXR-α using HMGS-PPRE as a probe. Antibody supershift experiments were subsequently performed using either anti-PPAR-α antibody (lanes 7, 8, 10, and 12) or anti-PPAR-γ1 antibody (lanes 14, 16, 18, and 19). Lane 8: pre-incubation of anti-PPAR-α antibody with its immunizing peptide. Lane 19: pre-incubation of anti-PPAR-γ1 antibody with its immunizing peptide. α, PPAR-α protein; δ, PPAR-δ (β) protein; γ1, PPAR-γ1 protein; PPAR/RXR, PPAR isoform/RXR-α heterodimers; Supershift, antibody supershifted PPAR isoform/RXR-α heterodimers.
cells (indicated by an arrow) and some epithelial cells. The immunohistochemical staining was completely inhibited by peptide absorption (lower left), indicating that the staining was specific. In the medulla, PPAR-α was weakly expressed at the nuclei of the loop of Henle and medullary collecting ducts (lower right). PPAR-α expression was also observed in both the intima and media of renal vasculatures (inset at upper left). The discrepancy between the immunoblot analyses and immunohistochemical staining with respect to PPAR-α expression in the medulla may also have been due to the difference of detection threshold level between them. The results of the immunohistochemical studies using anti-PPAR-γ 1 antibody are shown in Fig. 6B . In the cortex (upper left and upper right), PPAR-γ 1 was also expressed in the nuclei of glomeruli, proximal tubules (indicated by a large arrowhead), and distal tubules (indicated by a small arrowhead). PPAR-γ 1 was shown to be expressed in mesangial cells (indicated by an arrow) and epithelial cells in the glomeruli. The specificity of the staining was confirmed by peptide absorption (lower left). PPAR-γ 1 was also expressed in the nuclei of the loop of Henle and medullary collecting ducts (lower right) in the medulla. PPAR-γ 1 expression was also observed in both the intima and media of renal vasculatures (inset of upper left). These data suggest that both PPAR-α (lanes 1, 3, 5, 7, and 9) or the renal medulla (lanes 2, 4, 
Fig. 5. Analyses of PPAR isoform expression in the rat kidney. A: Western immunoblot analyses of the rat kidney nuclear extracts using anti-PPAR antibodies. Nuclear extracts of the renal cortex
6, 8, and 10) were electrophoresed, and immunoblot analyses using anti-PPAR-α antibody (lanes 1-4), anti-PPAR-γ1 antibody (lanes 5-8), or anti-PPAR-γ2 antibody (lanes 9 and 10) were performed. Lanes 3 and 4: pre-incubation of anti-PPAR-α antibody with its immunizing peptide. Lanes 7 and 8: pre-incubation of anti-PPAR-γ1 antibody with its immunizing peptide. B: Antibody supershift experiments in EMSA of the rat kidney nuclear extracts using anti-PPAR antibodies. EMSA using the rat kidney nuclear extracts obtained from cortex (lanes 2-5, 11 and 12) or medulla (lanes 6-9, 13 and 14) was performed using HMGS-PPRE as a probe. Antibody supershift experiments were subsequently performed using either non-immune rabbit serum (lanes 3 and 7), anti-PPAR-α antibody (lanes 4 and 8), or anti-PPAR-γ1 antibody (lanes 5 and 9). In lanes 12 and 14, the samples were co-incubated with a 100-fold excess of unlabeled oligonucleotides for HMGS-PPRE (Competitor). Protein-DNA complexes are indicated by arrows (Protein-DNA Complexes). Supershift, antibody supershifted Protein-DNA complexes; NE, nuclear extracts; NI, non-immune rabbit serum; α, anti-PPAR-α antibody; γ1, anti-PPAR-γ1 antibody. C: Semi-quantitative RT-PCR of the rat kidney total RNAs using specific primers for PPAR-γ1. Total RNAs extracted from the rat kidneys were subjected to semiquantitative RT-PCR using specific primers for rat PPAR-γ1 and β-actin. Lane 1: PCR products of the rat kidney total RNAs obtained from the cortex. Lane 2: PCR products of the rat kidney total RNAs obtained from the medulla.
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and -γ 1 proteins are widely expressed along the nephron segments.
Discussion
We have developed isoform-specific polyclonal antibodies against PPAR-α, -γ 1, and -γ 2 to study their protein expression. The specificity of these antibodies was demonstrated by their ability to recognize in vitro translated mouse PPAR-α, -γ 1, and -γ 2 proteins, respectively, as revealed by Western immunoblot analyses, immunoprecipitations, and supershift experiments in EMSA. Each antibody, therefore, can recog- (11) (12) (13) , although these expressions have mainly been demonstrated at the mRNA level. There exist several discrepancies between our study and previous reports. Regarding PPAR-α, we observed its expression widely along the nephron segments (glomeruli, proximal and distal tubules, the loop of Henle, medullary collecting ducts, and intima/media of renal vasculatures), whereas the previous studies reported that PPAR-α expression was mainly localized to the proximal tubules (11) (12) (13) . Regarding PPAR-γ, we also observed that PPAR-γ 1, but not PPAR-γ 2, was expressed widely along the nephron segments (glomeruli, proximal and distal tubules, the loop of Henle, medullary collecting ducts, and intima/media of renal vasculatures). Since the expression of PPAR-γ in glomeruli has so far been reported only in rats undergoing 5/6 nephrectomy (10) and TZDs-treated rabbits (21) , this is the first report describing PPAR-γ (γ 1) expression in normal glomeruli. In particular, mesangial and epithelial cells in glomeruli were observed to express PPAR-γ 1. In support of our data, PPAR-γ has been reported to be expressed in cultured mesangial cells (22) (23) (24) . Our data thus demonstrated a broad expression of PPAR-γ 1 protein in the kidney, predominantly in the cortex, which is discrepant with previous reports in which the PPAR-γ mRNA expression was mainly localized to the medulla (11-13). Since we also observed more abundant PPAR-γ 1 mRNA expression in the medulla than in the cortex, the discrepancy between our data and previous reports may simply be due to the difference of PPAR-γ 1 expression between the mRNA level and protein level. We therefore speculate that PPAR-γ 1 mRNA in the cortex is more prone to be translated into protein than PPAR-γ 1 mRNA in the medulla, or, alternatively, PPAR-γ 1 protein in the medulla is more prone to be degraded than PPAR-γ 1 protein in the cortex. Their precise mechanisms remain to be examined.
Fig. 6. Immunohistochemical analyses using anti-PPAR antibodies in the rat kidney. A: Immunostaining using anti-PPAR-α antibody. Renal cortex: upper left (magnification: 100) and upper right ( 200). Peptide absorption (cortex): lower left ( 100). Renal medulla: lower right ( 100). Inset at upper left: renal vasculatures ( 400
Recent studies have focused on the functions of PPARs in the kidney. Regarding PPAR-α, it is known to be involved in the control of fatty acid β-oxidation (4, 5) . PPAR-α is also reported to regulate cytochrome P450 4A genes through their PPRE at proximal tubules in the kidney (4, 25) , and may regulate sodium metabolism (4) and blood pressure (26) . Moreover, Kamijo et al. recently reported that PPAR-α in the proximal tubules was involved in the maintenance of ATP homeostasis to degrade absorbed proteins, including albumin, as revealed by increased urinary albumin excretion in starved PPAR-α-null mice (6) . Regarding PPAR-γ, its ligand TZDs have recently been reported to ameliorate albuminuria in diabetic rats (7) (8) (9) , and to reduce proteinuria and glomerulosclerosis in 5/6 nephrectomized rats (10) . Moreover, TZDs are known to cause fluid retention and edema as side effects (27) . Our studies have demonstrated wide expression of PPAR-γ (γ 1) along the nephron segments, including mesangial and epithelial cells in glomeruli, proximal and distal tubules, the loop of Henle, and medullary collecting ducts. Therefore, the above-described effects of TZDs may be mediated through PPAR-γ (γ 1) activation. We have recently reported the inhibition of angiotensin II (AII) type 1 receptor (AT1R) expression by TZDs through PPAR-γ activation in vascular smooth muscle cells (VSMCs) (19, 28) . In the kidney, AT1R is also expressed in mesangial cells, proximal and distal tubules, and collecting ducts (29) . Moreover, AII is reported to participate in cell proliferation and production of extracellular matrix in mesangial cells (30) and in reabsorption of water and sodium in renal tubules (31) through AT1R activation in the kidney. PPAR-γ activation may possibly inhibit AT1R expression in mesangial cells and tubules, and exert a beneficial effect against hypertension and nephrosclerosis. Moreover, we have recently demonstrated that PPAR-γ activation leads to the inhibition of both thromboxane (TX) receptor expression in VSMCs (17, 28) and TX synthase expression in macrophage (32) . TX is known to increase tubuloglomerular feedback in the kidney, which may result in the retention of fluid and salt (33) , and has been implicated in various renal diseases (34, 35) . Inhibition of the TX system by PPAR-γ activation may protect against the progression of hypertension and renal damage.
Our studies have demonstrated that both PPAR-α and -γ 1 proteins are more widely expressed along the nephron segments than previously reported. Although the activation of PPARs may possibly function against the progression of hypertension and nephrosclerosis in the kidney, further studies are needed to clarify the functional significance of PPARs in the kidney, including studies to identify their novel target genes along the nephron segments.
